Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 70, Iss. 5, pp. 962-969
Open Access | Times Cited: 352

Showing 1-25 of 352 citing articles:

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 631
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 9, pp. 599-612
Closed Access | Times Cited: 569
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
Norbert Stefan, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 4, pp. 284-296
Closed Access | Times Cited: 391
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
Alessandro Mantovani, Alessandro Csermely, Graziana Petracca, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 903-913
Open Access | Times Cited: 376
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
Giovanni Targher, Herbert Tilg, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 7, pp. 578-588
Open Access | Times Cited: 361
Changing epidemiology, global trends and implications for outcomes of NAFLD
Vincent Wai‐Sun Wong, Mattias Ekstedt, Grace Lai‐Hung Wong, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 842-852
Open Access | Times Cited: 271
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 71, Iss. 1, pp. 156-162
Open Access | Times Cited: 259
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 254
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2021) Vol. 71, Iss. 4, pp. 778-788
Open Access | Times Cited: 245
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Metabolites (2021) Vol. 11, Iss. 2, pp. 73-73
Open Access | Times Cited: 214
Non-alcoholic fatty liver disease: A patient guideline
Sven Francque, Giulio Marchesini, Achim Kautz, et al.
JHEP Reports (2021) Vol. 3, Iss. 5, pp. 100322-100322
Open Access | Times Cited: 204
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
Tom H. Karlsen, Nick Sheron, Shira Zelber‐Sagi, et al.
The Lancet (2021) Vol. 399, Iss. 10319, pp. 61-116
Open Access | Times Cited: 170
Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease
Vincent Wai‐Sun Wong, Grace Lai‐Hung Wong, Jean Woo, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 10, pp. 2161-2171.e5
Open Access | Times Cited: 168
Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons
Michael H. Le, David M. Le, Thomas C. Baez, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 287-295
Closed Access | Times Cited: 153
Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
Soo Lim, Jin–Wook Kim, Giovanni Targher
Trends in Endocrinology and Metabolism (2021) Vol. 32, Iss. 7, pp. 500-514
Closed Access | Times Cited: 147
Association of metabolic dysfunction-associated fatty liver disease with kidney disease
Ting-Yao Wang, Rui-Fang Wang, Zhi-Ying Bu, et al.
Nature Reviews Nephrology (2022) Vol. 18, Iss. 4, pp. 259-268
Open Access | Times Cited: 140
Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China
Yebei Liang, Hongli Chen, Yuexing Liu, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 1, pp. 88-97
Open Access | Times Cited: 135
The role of hepatokines in NAFLD
Norbert Stefan, Fritz Schick, Andreas L. Birkenfeld, et al.
Cell Metabolism (2023) Vol. 35, Iss. 2, pp. 236-252
Open Access | Times Cited: 135
Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis
Elina Cho, C. Ang, Jingxuan Quek, et al.
Gut (2023) Vol. 72, Iss. 11, pp. 2138-2148
Closed Access | Times Cited: 111
Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Haleh Chehrehgosha, Masoudreza Sohrabi, Faramarz Ismail‐Beigi, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 3, pp. 843-861
Open Access | Times Cited: 110
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors
Emir Muzurović, Carol Chiung‐Hui Peng, Matthew J. Belanger, et al.
Hypertension (2022) Vol. 79, Iss. 7, pp. 1319-1326
Closed Access | Times Cited: 84
Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties
Alina M. Allen, Jeffrey V. Lazarus, Zobair M. Younossi
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 209-217
Open Access | Times Cited: 76
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
Zobair M. Younossi, Pegah Golabi, Jillian Kallman Price, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 10, pp. 1999-2010.e8
Closed Access | Times Cited: 55
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 51
Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies
Kai En Chan, Elden Yen Hng Ong, Charlotte Hui Chung, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 3, pp. 488-498.e14
Closed Access | Times Cited: 49
Page 1 - Next Page

Scroll to top